Thrilled to share our latest work - we describe a novel and therapeutically relevant mechanism underlying dysregulation of innate immune receptor C5aR1 in the tumour microenvironment. Thanks and congratulations to all authors! www.nature.com/articles/s41...

🎉New vacancy: Postdoctoral Researcher - Cell Permeant Antibodies for the Treatment of Cancer Join the Department of Oncology as a postdoc working on an innovative MRC GAP Award grant project focused on developing novel cancer therapeutics. For full details: www.oncology.ox.ac.uk/about-us/wor...

#REVIEW 🚨 Hanahan, Michielin & Pittet discuss how, nearly all cell types in the tumour microenvironment can be programmed to mediate — as functionally distinct subtypes — immunosuppressive programmes. 📖 👇 https://bit.ly/3NGkl...

Convergent inducers and effectors of T cell paralysis in the tumour microenvironment - Nature Reviews Cancer

In this Review, Hanahan et al. discuss how, in response to tumorigenesis, nearly all cell types in the tumour microenvironment can be programmed to mediate — as functionally distinct subtypes — immunosuppressive programmes.

bit.ly

www.cancer.ox.ac.uk/news/oxford-...

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent ...

cancer.ox.ac.uk

Tune in to BBC Radio 4 at 5pm to hear from Prof. Anna Schuh! Anna will be discussing her new study on the development of a highly sensitive blood test that detects multiple cancers at their earliest stages, published today in Nature Communications. www.bbc.co.uk/programmes/m...

BBC Radio 4 - PM, 08/01/2025

Afternoon news and current affairs programme

bbc.co.uk

Want to learn about the role of the complement system in the response to cytotoxic cancer therapy? Check out our latest review: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...